1,4-Diphenylcyclopenta<1,2>-oxazin | 109940-24-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 1,4-Diphenylcyclopenta<1,2>-oxazin
• 英文别名: 1,4-diphenyl-cyclopenta[d][1,2]oxazine；1,4-diphenyl-cyclopent[d][1,2]oxazine；1,4-Diphenyl-cyclopent[d][1,2]oxazin；1,4-Diphenylcyclopenta[d][1,2]oxazine；1,4-diphenylcyclopenta[d]oxazine
• CAS: 109940-24-1
• 化学式: C₁₉H₁₃NO
• 分子量: 271.318
• InChiKey: SZURTHZUMQPHPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-benzoyl-6-phenyl-6-hydroxypentafulvene 在 吡啶 、 盐酸 、 乙醇 、 羟胺 作用下， 生成 1,4-Diphenylcyclopenta<1,2>-oxazin
  参考文献：
  名称：

  The Benzoylation of Cyclopentadienyllithium

  摘要：

  DOI：

  10.1021/ja01575a038

文献信息

• Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
  申请人：Cenix Bioscience GmbH

  公开号：EP1832283A1

  公开（公告）日：2007-09-12

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

  本发明涉及使用清道夫受体类蛋白，特别是 ScarB1 的抑制剂来生产治疗和/或预防涉及肝细胞和/或造血细胞，特别是疟疾的感染的药物。
• Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
  申请人：Hannus Michael

  公开号：US20090324580A1

  公开（公告）日：2009-12-31

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES
  申请人：HANNUS MICHAEL

  公开号：US20120276121A1

  公开（公告）日：2012-11-01

  The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
• US8507546B2
  申请人：——

  公开号：US8507546B2

  公开（公告）日：2013-08-13
• US9884851B2
  申请人：——

  公开号：US9884851B2

  公开（公告）日：2018-02-06